All In Biotech

Drug Trial Radar · NCT07377578

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Randomized, Open-label, Multicenter, Phase III Clinical Study Comparing Rocbrutinib Monotherapy Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (PRIME Study)

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

394

Planned (sponsor's estimate)

Start

Feb 5, 2026

Primary completion

May 30, 2031

Study completion Jan 30, 2033

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).

Conditions

  • Mantle Cell Lymphoma

Interventions

  • RocbrutinibDrug

    Rocbrutinib at 150 mg once daily orally until disease progression or unacceptable toxicity

  • IbrutinibDrug

    Ibrutinib, 560 mg once daily orally and continuously

  • AcalabrutinibDrug

    Acalabrutinib, 100 mg twice daily orally and continuously

  • ZanubrutinibDrug

    Zanubrutinib, 160 mg twice daily orally and continuously

  • OrelabrutinibDrug

    Orelabrutinib, 150 mg once daily orally and continuously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by IRCTime frame: approximately 30 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.